Loading clinical trials...
Loading clinical trials...
This is a phase IV study of indacaterol 75 μg single-dose compared to placebo in moderate-severe COPD patients with breathing symptoms to assess time to patient's perception of onset of effect.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT06847061 · Chronic Obstructive Pulmonary Disease (COPD
NCT07307781 · Chronic Obstructive Pulmonary Disease (COPD)
NCT07383896 · Asthma, COPD
NCT07112235 · COPD (Chronic Obstructive Pulmonary Disease), Rhinovirus Infection, and more
NCT07518472 · Pulmonary Disease, Chronic Obstructive (COPD)
Novartis Investigative Site
Fullerton, California
Novartis Investigative Site
Saint Charles, Missouri
Novartis Investigative Site
Charlotte, North Carolina
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions